FinChain and KuCoin Enter into Partnership
FUSD Integrated as Collateral Asset into KuCoin RWA Collateral Mirroring Solution (RCMS), Unlocking the Application Value of Yield ‑ Bearing RWA Digital Assets in Offshore Trading and Capital Efficiency Management HONG KONG, Aug. 31, 2026...
Furniture China and Maison Shanghai 2026 Enter Final Countdown
SHANGHAI, Aug. 25, 2026 /PRNewswire/ -- With less than two weeks to go, Furniture China and Maison Shanghai 2026, organized by CNFA and IM Sinoexpo, are entering the final countdown to their September return to Shanghai Pudong, bringing together...
Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
TAIPEI, Aug. 24, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the...
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages Based on the initial arrangements, the total invoiced amount...
ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
SHANGHAI, Aug. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the Investigational New Drug (IND) application for AK0406 injection, the company's first long-acting antiviral drug‑Fc conjugate (AFC)...
Hitek Announces Entry into Share Purchase Agreement to Acquire an Advertising and Digital Marketing Company
XIAMEN, China, August 3, 2026 /PRNewswire/ -- Hitek Global Inc. (Nasdaq: HKIT) (the "Company" or "Hitek"), an information technology consulting and solutions provider, today announced that, on August 3, 2026, it entered into a Share Purchase...
Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology...
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
SHANGHAI, July 2, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to...
Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases
CAMBRIDGE, Mass., July 2, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, today announced a strategic collaboration with Lonza to...
METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager
HONG KONG and NEW YORK, June 30, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, today announced it has entered into an exclusive global licensing agreement with Boulevard Bio ("Boulevard"), a U.S....